

FOR IMMEDIATE RELEASE

STIFEL NICOLAUS HOSTS ANNUAL HEALTHCARE CONFERENCE

BOSTON, September 15, 2010 – Stifel, Nicolaus & Company, Incorporated, a full-service brokerage and investment banking firm, will host its Annual Healthcare Conference, September 15-17, 2010 at the Four Seasons Hotel in Boston. Institutional investors and company management will gather for this three-day conference, which will focus on opportunities and challenges in the healthcare industry for the remainder of 2010 and beyond.

The conference will showcase presentations from over 180 established and emerging public and private companies, including those engaged in biotechnology, diagnostics, healthcare IT & services, life science technology, major and specialty pharmaceuticals, and medical devices.

“We remain committed to broadening and deepening our coverage of the healthcare sector, one of the most important areas of growth in the U.S. economy. Despite broad economic weakness over the last year, healthcare spending continues to increase as a percentage of GDP. According to the Office of the Actuary, Center for Medicare and Medicaid Services (CMS), aggregate Healthcare spending, at 17% of GDP in 2009, is expected to reach 21% by 2019. Healthcare will continue to outpace growth of the overall economy, in our opinion — fueling robust, long-term investment opportunities,” said Ronald J. Kruszewski, Chairman, President, and Chief Executive Officer of Stifel Financial Corp.

The conference commences Wednesday morning and will be led by Stifel Nicolaus’ eight senior healthcare research analysts: Thomas Carroll, health services; Charles Chon, medical devices; Jerry Doctrow, healthcare providers & REITs; Steven Halper, healthcare information technology and pharmaceutical services; Thomas Kouchoukos, medical devices; Annabel Samimy, specialty pharmaceuticals; Maged Shenouda, biotechnology; and Stephen Willey, biotechnology. Analysts will offer insight into the major trends impacting their respective sectors.

In addition to company insights, our keynote presentations feature first-class talent who are expected to challenge our perspectives and provide additional insights on the current debate regarding healthcare reform. We are pleased to host Nancy-Ann DeParle, Director of the White House Office for Health Reform, and Arnold Milstein, MD, MPH, Professor of Medicine and Director of the Clinical Excellence Research Center, Stanford University.

A full list of company participants includes:

ACADIA Pharmaceuticals Inc.	Alnylam Pharmaceuticals, Inc.
Achillion Pharmaceuticals	Alphatec Holdings, Inc.
Acura Pharmaceuticals, Inc.	Altea Therapeutics
Affymax, Inc.	Amedisys, Inc.
Affymetrix, Inc.	American Medical Systems, Inc.
Agilent Technologies, Inc.	AmerisourceBergen Corporation
Alder Biopharmaceuticals Inc.	Anadys Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.	AngioChem
Alimera Sciences, Inc.	AngioDynamics, Inc.
Allergan, Inc.	Arcadian Management Services, Inc.
Allscripts Healthcare Solutions, Inc.	Ardea Biosciences, Inc.

ArQule, Inc.
Array BioPharma Inc.
Arstasis
athenahealth, Inc.
AutoGenomics, Inc.
Auxilium Pharmaceuticals, Inc.
Beckman Coulter, Inc.
BioBehavioral Diagnostics Company
BioDelivery Sciences International, Inc.
Biogen Idec Inc.
BioMarin Pharmaceutical, Inc.
Bio-Rad Laboratories, Inc.
Cadence Pharmaceuticals, Inc.
CambridgeSoft Corporation
Cardinal Health, Inc.
Celator Pharmaceuticals, Inc.
Celgene Corporation
Cempra Pharmaceuticals
Centene Corporation
Cephalon, Inc.
Cepheid
Ceregene, Inc.
Cerner Corporation
Conceptus, Inc.
Concert Pharmaceuticals Inc.
ConforMIS, Inc
CONMED Corporation
Corcept Therapeutics Incorporated
Covance Inc.
Cubist Pharmaceuticals, Inc.
Cumberland Pharmacueticals Inc.
Cytochroma Inc.
DFine, Inc.
Dionex Corporation
Dyax Corp.
EGEN, Inc.
eHealth, Inc.
Emdeon Corporation
Endo Pharmaceuticals
Eurand (US)
Exactech, Inc.
Exelixis, Inc.
Express Scripts, Inc.
ForteBio
Genomic Health, Inc.
Gen-Probe Incorporated
Gentiva Health Services, Inc.
Genzyme Corporation
Geron Corporation
Given Imaging Ltd.
GlobeImmune, Inc.
HealthSpring, Inc
Hill-Rom Holdings, Inc.
Human Genome Sciences, Inc.
Idenix Pharmaceuticals, Inc.
Ikonisys Inc.
ImmunoGen, Inc.
Inhibitex, Inc.
Inovio Pharmaceuticals
Inspire Pharmaceuticals, Inc.
Insulet Corporation
Integra LifeSciences Corporation
InterMune, Inc.
ISIS Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc.
Keryx Biopharmaceuticals
Kindred Healthcare, Inc.
Lexicon Pharmaceuticals, Inc.
Ligand Pharmaceuticals Inc.
Light Sciences Oncology Inc.
Lincare Holdings Inc.
Logical Therapeutics, Inc.
MacroGenics Inc.
MAP Pharmaceuticals Inc.
Masimo Corporation
McKesson Corporation
MedAptus, Inc.
MedAssets, Inc.
Medicis Pharmaceutical Corporation
MEDNAX, Inc.
Medtronic, Inc.
Meridian Bioscience, Inc.
Merit Medical Systems, Inc.
Merrimack Pharmaceuticals, Inc.
Myriad Genetics, Inc.
Natus Medical Incorporated
Neoprobe Corporation
NeurAxon Inc.
Neurocrine Biosciences, Inc.
Neuronetics, Inc.
NeuroPace, Inc.
Novadaq Technologies Inc.
Novavax, Inc.
NuPathe, Inc.
Obagi Medical Products, Inc.
Omnicare, Inc.
Omnicell, Inc.
OmniGuide, Inc.

OncoGenex Pharmaceuticals Inc	Spectrum Pharmaceuticals, Inc.
Orion HealthCorp, Inc.	Stereotaxis, Inc.
Orthofix International N.V.	Supernus Pharmaceuticals, Inc.
Orthovita, Inc.	SXC Health Solutions Corporation
Osiris Therapeutics, Inc.	Symmetry Medical, Inc.
Owens & Minor, Inc.	T2 Biosystems, Inc.
PAREXEL International Corporation	Targacept, Inc.
PatientKeeper, Inc.	Tekmira Pharmaceuticals Corporation
PerkinElmer, Inc.	Teleflex Incorporated
Pharmacyclics, Inc.	The Advisory Board Company
PharMerica Corporation	The Cooper Companies, Inc.
Precision Therapeutics, Inc.	The Ensign Group, Inc.
PTC Therapeutics, Inc.	The Spectranetics Corporation
Qiagen N.V.	Theravance, Inc.
Quality Systems, Inc.	Transcept Pharmaceuticals, Inc.
RainDance Technologies	TransEnterix, Inc.
Regado Biosciences, Inc.	Tranzyme Pharma
Regulus Therapeutics Inc.	Trius Therapeutics
RehabCare Group, Inc.	U.S. Preventive Medicine
Response Biomedical Corporation	Unilife Corporation
Revance Therapeutics, Inc.	Vanguard Health Systems
Rib-X Pharmaceuticals, Inc.	Vapotherm
Rigel Pharmaceuticals, Inc.	Vascular Solutions, Inc.
S*BIO Pte Ltd.	Vical Incorporated
Salix Pharmaceuticals, Ltd.	ViroPharma Incorporated
Santarus, Inc.	Vitae Pharmaceuticals
SCYNEXIS, Inc.	Vital Images, Inc.
Seattle Genetics, Inc.	Vivus, Inc.
Sigma-Aldrich Corporation	WellCare Health Plans, Inc
SkinMedica, Inc.	WellPoint, Inc.
Small Bone Innovations, Inc.	Wright Medical Group, Inc.
SonoSite, Inc.	XDx, Inc.

Company Information

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel clients are primarily served in the U.S. through 310 offices in 43 states and the District of Columbia through Stifel, Nicolaus & Company, Incorporated and Thomas Weisel Partners LLC, and in two Canadian provinces through Stifel Nicolaus Canada Inc. Clients in the United Kingdom and Europe are served through offices of Stifel Nicolaus Limited and Thomas Weisel Partners International Limited. Each of the broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, commercial and retail banking, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank & Trust offers a full range of consumer and commercial lending solutions. To learn more about Stifel, please visit the company's web site at www.stifel.com.

Investor Relations Contact:

Sarah Anderson
(415) 364-2500
investorrelations@stifel.com